404 related articles for article (PubMed ID: 10804092)
1. Clinical strategy for the development of angiogenesis inhibitors.
Carter SK
Oncologist; 2000; 5 Suppl 1():51-4. PubMed ID: 10804092
[TBL] [Abstract][Full Text] [Related]
2. Angiogenesis inhibition in solid tumors.
Rosen LS
Cancer J; 2001; 7 Suppl 3():S120-8. PubMed ID: 11779082
[TBL] [Abstract][Full Text] [Related]
3. The role of vascular endothelial growth factor (VEGF) in AIDS-related Kaposi's sarcoma.
Arastéh K; Hannah A
Oncologist; 2000; 5 Suppl 1():28-31. PubMed ID: 10804088
[TBL] [Abstract][Full Text] [Related]
4. Angiogenesis inhibitors in the treatment of lung cancer.
Shepherd FA
Lung Cancer; 2001 Dec; 34 Suppl 3():S81-9. PubMed ID: 11740999
[TBL] [Abstract][Full Text] [Related]
5. Measuring VEGF-Flk-1 activity and consequences of VEGF-Flk-1 targeting in vivo using intravital microscopy: clinical applications.
Vajkoczy P; Thurnher A; Hirth KP; Schilling L; Schmiedek P; Ullrich A; Menger MD
Oncologist; 2000; 5 Suppl 1():16-9. PubMed ID: 10804086
[TBL] [Abstract][Full Text] [Related]
6. Targeting vascular endothelial growth factor blockade: ascites and pleural effusion formation.
Verheul HM; Hoekman K; Jorna AS; Smit EF; Pinedo HM
Oncologist; 2000; 5 Suppl 1():45-50. PubMed ID: 10804091
[TBL] [Abstract][Full Text] [Related]
7. von Hippel-Lindau syndrome: target for anti-vascular endothelial growth factor (VEGF) receptor therapy.
Harris AL
Oncologist; 2000; 5 Suppl 1():32-6. PubMed ID: 10804089
[TBL] [Abstract][Full Text] [Related]
8. Vascular endothelial growth factor in human colon cancer: biology and therapeutic implications.
Ellis LM; Takahashi Y; Liu W; Shaheen RM
Oncologist; 2000; 5 Suppl 1():11-5. PubMed ID: 10804085
[TBL] [Abstract][Full Text] [Related]
9. Targeted therapy in non-small-cell lung cancer.
Herbst RS
Oncology (Williston Park); 2002 Sep; 16(9 Suppl 9):19-24. PubMed ID: 12375797
[TBL] [Abstract][Full Text] [Related]
10. [New therapeutic targets and strategies in lung cancer].
Sánchez De Cos Escuín J
Arch Bronconeumol; 2002 Aug; 38(8):386-91. PubMed ID: 12199921
[No Abstract] [Full Text] [Related]
11. Role of angiogenesis inhibitors in acute myeloid leukemia.
Fiedler W; Staib P; Kuse R; Dührsen U; Flasshove M; Cavalli F; Hossfeld DK; Berdel WE
Cancer J; 2001; 7 Suppl 3():S129-33. PubMed ID: 11779083
[TBL] [Abstract][Full Text] [Related]
12. New chemotherapeutic agents: update of major chemoradiation trials in solid tumors.
Curran WJ
Oncology; 2002; 63 Suppl 2():29-38. PubMed ID: 12466642
[TBL] [Abstract][Full Text] [Related]
13. SU6668, a multitargeted angiogenesis inhibitor.
Hoekman K
Cancer J; 2001; 7 Suppl 3():S134-8. PubMed ID: 11779084
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of vascular endothelial growth factor-associated tyrosine kinase activity with SU5416 blocks sprouting in the microvascular endothelial cell spheroid model of angiogenesis.
Haspel HC; Scicli GM; McMahon G; Scicli AG
Microvasc Res; 2002 May; 63(3):304-15. PubMed ID: 11969307
[TBL] [Abstract][Full Text] [Related]
15. Advances in the use of angiogenesis inhibitors in cancer.
Pinedo HM
Cancer J; 2001; 7 Suppl 3():S107-8. PubMed ID: 11779080
[No Abstract] [Full Text] [Related]
16. Pharmacia's SU5416 not effective.
Expert Rev Anticancer Ther; 2002 Feb; 2(1):5. PubMed ID: 12113066
[No Abstract] [Full Text] [Related]
17. Angiogenesis inhibitors in clinical development for lung cancer.
Herbst RS; Hidalgo M; Pierson AS; Holden SN; Bergen M; Eckhardt SG
Semin Oncol; 2002 Feb; 29(1 Suppl 4):66-77. PubMed ID: 11894016
[TBL] [Abstract][Full Text] [Related]
18. New drugs in cancer therapy, National Tumor Institute, Naples, 17-18 June 2004.
Caponigro F; Basile M; de Rosa V; Normanno N
Anticancer Drugs; 2005 Feb; 16(2):211-21. PubMed ID: 15655420
[TBL] [Abstract][Full Text] [Related]
19. Expression profiling of blood samples from an SU5416 Phase III metastatic colorectal cancer clinical trial: a novel strategy for biomarker identification.
DePrimo SE; Wong LM; Khatry DB; Nicholas SL; Manning WC; Smolich BD; O'Farrell AM; Cherrington JM
BMC Cancer; 2003 Feb; 3():3. PubMed ID: 12657164
[TBL] [Abstract][Full Text] [Related]
20. Endothelial survival factors as targets for antineoplastic therapy.
Reinmuth N; Stoeltzing O; Liu W; Ahmad SA; Jung YD; Fan F; Parikh A; Ellis LM
Cancer J; 2001; 7 Suppl 3():S109-19. PubMed ID: 11779081
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
